Compare Invesco Solar ETF (TAN) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Solar ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Invesco Solar ETF trades at $42.4 (market cap $881.52M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 5.5× Invesco Solar ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Solar ETF for 35 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TAN | TVTX | |
|---|---|---|
Market Cap | $881.52M | $4.88B |
Volume | 3,915,267 | 1,668,577 |
Sector | Sector/Thematic | Health |
52-Week High | $73.95 | $67.52 |
52-Week Low | $42.64 | $26.79 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAN trades at $44.38, up 2.07% today but facing bearish technical signals with sell signals outweighing buys 11-8. The solar ETF shows mixed sentiment amid sector volatility, with recent news highlighting both policy tailwinds from U.S. tariffs and headwinds from high borrowing costs impacting project financing.
Outlook remains cautious due to sector-specific risks including interest rate sensitivity and market saturation concerns. While geopolitical shifts favor renewable energy adoption, TAN's high expense ratio and historical underperformance versus broad market indices present challenges for investors seeking stable returns.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
